All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

September 21st 2022

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Fianlimab Plus Cemiplimab Generates Meaningful Responses in Anti–PD-1/PD-L1–Naïve Advanced Melanoma

September 21st 2022

The combination of fianlimab and cemiplimab demonstrated clinically meaningful activity in patients with advanced melanoma who were naïve to anti–PD-1/PD-L1 therapy.

Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers

September 21st 2022

Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.

Rusfertide May Eliminate Need for Frequent Phlebotomies in Polycythemia Vera

September 21st 2022

Srdan Verstovsek, MD, PhD, discusses the benefits of rusfertide, an agent currently under evaluation in patients with polycythemia vera. In addition, he lays out the distinctions between low-risk and high-risk polycythemia vera and explains the benefits of this drug in both populations.

UAMS Breast Cancer Program Earns National Reaccreditation

September 21st 2022

The Breast Cancer program at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has earned reaccreditation from the National Accreditation Program for Breast Centers.

Exploring High-Intensity Focused Ultrasound as an Organ-Sparing Option for Prostate Cancer

September 21st 2022

The definitive treatment of prostate cancer has historically relied on whole-gland treatment.

FDA Approves Pedmark for Prevention of Platinum-Induced Ototoxicity in Pediatric Solid Tumors

September 20th 2022

The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.

Frontline Immunotherapy Combos Linked With Higher CR Rates Than Anti-VEGF Therapy in mRCC

September 20th 2022

Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.

Frontline Toripalimab Plus Chemotherapy Approved in China for Advanced Nonsquamous NSCLC

September 20th 2022

The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab plus pemetrexed and platinum as a frontline treatment in unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer not harboring EGFR mutations or ALK fusions.

Immunotherapy Prior to Development of Brain Metastases Improves Survival in Metastatic RCC

September 20th 2022

Treatment with immunotherapy prior to the development of brain metastases improved the median overall survival in patients with metastatic renal cell carcinoma.

Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADT

September 20th 2022

Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20th 2022

An analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.

Florida Cancer Specialists & Research Institute Celebrates Addition of Next Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care

September 20th 2022

Florida Cancer Specialists & Research Institute, LLC celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.

EphrinB2 Emerges as Targetable Option in Urothelial Carcinoma

September 20th 2022

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

HRQOL Is Maintained With Nivolumab in Real-World Population of Pretreated mRCC

September 20th 2022

Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.

Zanubrutinib Approaches European Approval for Marginal Zone Lymphoma

September 19th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib for use in adult patients with marginal zone lymphoma who have received at least 1 prior anti–CD20-based therapy.

FDA Grants Priority Review to Tucatinib/Trastuzumab Combo for Previously Treated HER2+ mCRC

September 19th 2022

The FDA has granted a priority review to a supplemental new drug application seeking the approval of tucatinib for use in combination with trastuzumab in adult patients with HER2-positive colorectal cancer who have received at least 1 prior treatment regimen for unresectable or metastatic disease.

FDA Grants Orphan Drug Designation to ATG-101 for Pancreatic Cancer

September 19th 2022

The FDA has granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer.

FDA Grants Orphan Drug Designation to Ezurpimtrostat for Cholangiocarcinoma

September 19th 2022

The FDA has granted an orphan drug designation to the novel autophagy/palmitoyl protein thioesterase-1 inhibitor ezurpimtrostat for the treatment of patients with cholangiocarcinoma.

Axi-cel Receives Positive Opinion from EU for DLBCL/HGBL

September 19th 2022

The European Medicines Agency Committee for Medicinal Products for Human Use has granted a positive opinion for axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.